Tuesday, 25 Feb 2020

You are here

Anti-IL-23 Beats IL-17 in Plaque Psoriasis

Lancet reports a head-to-head trial of antibodies against interleukin (IL)-23 and IL-17A in patients with moderate-to-severe psoriasis favored guselkumab with superior PASI 90 responses at week 48 (compared to secukinumab).

The ECLIPSE study was a phase 3 trial comparing an IL-23p19 inhibitor, guselkumab, to an IL-17A inhibitor, secukinumab. Patients were randomized to receive either guselkumab (100 mg at weeks 0 and 4 then every 8 weeks) or secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, and then every 4 weeks). The primary endpoint was the 90% reduction or more from baseline of Psoriasis Area and Severity Index (PASI 90 response) at week 48.

A total of 1048 patients were enrolled and the PASI 90 response at week 48 was:

  • 84% in the guselkumab group
  • 70% in the secukinumab group (p<0·0001)
  • Non-inferiority was established for other secondary endpoints 

Guselkumab is one of three IL-23 inhibitors approved for use in psoriasis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.